In this study, our data suggest that the re-expression of Fhit and its interaction with Hsp90 exerts an anti-tumor effect on human melanomas by modulating the C-Raf activity, especially when combined with Hsp90 inhibitors. Here, RAF1 is linked to neoplasm.